Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
OKYO Pharma Limited Sponsored ADR ( (OKYO) ) has shared an announcement.
On March 19, 2026, OKYO Pharma disclosed that Chief Development Officer and Director Gary Jacob acquired 30,980 of the company’s ordinary shares on Nasdaq at $1.59, increasing his total holding to 108,920 shares. The insider purchase, coming on the heels of positive Phase 2 data for urcosimod in neuropathic corneal pain and prior supportive results in dry eye disease, underscores executive confidence as the company prepares to launch a roughly 150-patient Phase 2b/3 trial later this year.
The share acquisition may be viewed by investors as a vote of confidence in OKYO’s lead program and overall strategic direction in ocular pain and inflammation. It also highlights management’s alignment with shareholders at a pivotal clinical inflection point, as the company seeks to advance urcosimod through late-stage development and potentially strengthen its competitive footing in the market for treatments targeting neuropathic corneal pain and related eye conditions.
The most recent analyst rating on (OKYO) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
Spark’s Take on OKYO Stock
According to Spark, TipRanks’ AI Analyst, OKYO is a Neutral.
The score is primarily held down by weak financial fundamentals (pre-revenue, ongoing losses, negative free cash flow, and negative equity) and bearish technicals (below key moving averages with negative MACD). Improved 2025 cost control and a debt-free balance sheet provide only limited offset.
To see Spark’s full report on OKYO stock, click here.
More about OKYO Pharma Limited Sponsored ADR
OKYO Pharma Limited is a clinical-stage biopharmaceutical company listed on the Nasdaq Capital Market and focused on developing innovative therapies for neuropathic corneal pain and inflammatory eye diseases. The company’s flagship drug candidate, urcosimod, targets ocular inflammation and pain, and recently completed a successful Phase 2 trial in subjects with neuropathic corneal pain, with a larger Phase 2b/3 multiple-dose study planned for the first half of this year.
Average Trading Volume: 271,117
Technical Sentiment Signal: Strong Sell
Current Market Cap: $83.22M
For a thorough assessment of OKYO stock, go to TipRanks’ Stock Analysis page.